Answers are grounded in this paper and cite their sources.
More than 170 million persons harbor chronic infection with hepatitis C virus (HCV), the leading indication for liver transplantation worldwide. For more than 20 years, treatment of chronic hepatitis C infection has relied on the use of the nonspecific antiviral cytokine interferon alfa, which induces hundreds of genes that collectively generate an antiviral state. In the early 1990s, treatment with interferon alfa resulted in a sustained virologic response in very few patients. The next two decades witnessed steady improvement; combining pegylated interferon alfa (peginterferon alfa) with ribavirin produced overall rates of sustained virologic response of 54 to 56%,1,2 with . . .
No takes yet. Share an insight, caveat, or question.
Raymond T. Chung (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: